Abstract: The invention disclosed herein includes a vitamin composition encapsulated in a soft or hard shell capsule, said vitamin composition comprising water soluble vitamin particles suspended in a fill liquid, wherein said water soluble vitamin particles are coated with a material that is substantially insoluble in the fill liquid and the shell of the capsule, but soluble in the gastrointestinal tract of a mammal, and the coated water soluble vitamin particles are of a size that are suitable for encapsulating as a suspension in said capsule. The invention also includes a process for manufacturing the same. Vitamin containing capsules according to this invention are discoloration-resistant.

Abstract: A dry powder layering process for preparing pharmaceutical compositions of the leukotriene antagonist zafirlukast. The process forms coated beads suitable for sprinkling on to food and drink.

Abstract: The use of compositions containing a mixture of a diol and an alpha-hydroxy acid in a semi-occluding vehicle for the topical treatment of hyperkeratotic skin diseases is provided.

Abstract: Oral pharmaceutical formulation comprising granules having an inert core coated with a layer, comprising a 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, a separating layer and an enteric coating layer, and a process for the preparation of such formulation using a melt coating technique for the preparation of the benzimidazole containing layer.

Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

Abstract: Microcapsules prepared by encapsulating an aqueous solution of a protein, drug or other bioactive substance inside a semi-permeable membrane by are disclosed. The microcapsules are formed by interfacial coacervation under conditions where the shear forces are limited to 0-100 dynes/cm2 at the interface. By placing the microcapsules in a high osmotic dewatering solution, the protein solution is gradually made saturated and then supersaturated, and the controlled nucleation and crystallization of the protein is achieved. The crystal-filled microcapsules prepared by this method can be conveniently harvested and stored while keeping the encapsulated crystals in essentially pristine condition due to the rugged, protective membrane. Because the membrane components themselves are x-ray transparent, large crystal-containing microcapsules can be individually selected, mounted in x-ray capillary tubes and subjected to high energy x-ray diffraction studies to determine the 3-D structure of the protein molecules.

Abstract: Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.

Abstract: A prepackaged disposable towelette and saline solution each separably held within a disposable sealed package. The towelette is presaturated with a neutralizing solution so that, as finger residue is rubbed off and absorbed into the fabric of the towelette, the finger skin pH is also substantially neutralized which minimizes eye irritation each time a contact lens user reinstalls each contact lens. The saline solution, held within a separate hermetically sealed ampule, rewets each contact lens before contact lens installation to further reduce eye irritation.

Abstract: A nail varnish or nailcare composition containing an aqueous dispersion of particles of acrylic polymer having a glass transition temperature (Tg) greater than or equal to 45° C. and a minimum film-forming temperature (MFT) such that Tg−MFT≦20° C., a first organic solvent having a boiling point measured at ambient pressure of greater than or equal to 225° C. and a second organic solvent having a boiling point measured at ambient pressure ranging from 70° C. to 180° C. A method of making up and/or caring for the nails which includes applying the composition to the nails. The nail composition is adherent to the nail, is bright and is easily removed with conventional removers.

Abstract: A biological material is prepared for use in ophthalmology by steps of providing animal pericardium, subjecting the animal pericardium to multiple steps of freezing and thawing in a salt solution and incubating the animal pericardium in a solution of ammonia and ethyl alcohol. The multiple steps of freezing and thawing are conducted in a mixture of about 0.9% sodium chloride solution and distilled water in about 1:1 proportions of sodium chloride solution to distilled water. The incubating step is conducted in a mixture of 1% ammonia solution and 1% ethyl alcohol solution in about 1:1 proportions of ammonia solution to ethyl alcohol solution over a period of 48 to 72 hours.

Abstract: The present invention relates to a preparation which contains at least one physiologically effective iron complex and at least one polyunsaturated fatty acid in free or chemically bonded form, in particular for use as a medication and/or food supplement. The preparation according to the invention may be preferably used for manufacturing a medication and/or food supplement for treating or the prevention of deficiency symptoms as they may occur during pregnancy and breastfeeding. Furthermore antioxidizing agents and folic acid may be contained in the preparation according to the invention.

Abstract: A microbead having a matrix core comprising a hydrophilic matrix and droplets of active material entrained therein, and a secondary layer adjacent to the outer surface of the matrix core. The secondary layer may be ionically complexed or hydrogen bonded to the matrix core surface. Compositions comprising the microbeads suspended in solution may be sprayable. The microbeads of the invention may be controllable by exposing the microbeads to high or low humidity or moisture.

Abstract: Disclosed are stable compositions which are effective as skin whitening agents, comprising alpha, beta or gamma substituted mono-, di or polyhydroxy or polycarboxy carboxylic acids; mono-, di, tri or polyhydroxy alkyl compound; and effective amounts of an inhibitor of tyrosinase and a pigmentation reversing reagent. Also disclosed are methods of forming stable compositions of the type described above.

Abstract: A nonwoven wipe suitable for use as a pre-moistened baby wipe comprised of thermoplastic fibers having a predetermined nominal fiber length, the wipe being calendar-embossed with a pattern comprising a plurality of discrete icons, each of the icons having an equivalent icon diameter of at least about one half the nominal fiber length, and the plurality of icons being separated one from another by an equivalent unbonded area diameter of at least about one half the nominal fiber length. In a preferred embodiment the nonwoven web is spunlaced, with a fiber composition of between about 40%-60% viscose, and the remainder thermoplastic fiber. The wipes of the present invention combine superior softness with embossed designs for better aesthetic appeal.

Abstract: A powder composition which is readily dispersible in a liquid such as water without clumping, comprises a powder the particles of which are uniformly coated with an effective amount of a surfactant, preferably Polysorbate-80, sufficient to enable the powder composition to readily disperse in the liquid. A process for making the powder composition that disperses readily in a liquid without clumping, comprises the step of continuously mixing a powder with an amount of a surfactant for a time sufficient to uniformly coat at least substantially all of the particles of the powder with the surfactant.

Abstract: Process for the preparation of pharmaceutical compositions comprising one or more polymers and one or more drugs by the extrusion and spheronization technique, wherein polymers belong to the group of the cross-linked amphiphilic polymers.

Abstract: A complex between carrageenan and a water soluble drug characterized in powder form having an average particle size comprised between 10 and 100 &mgr;m, and the basic water drug is contained in the complex in amounts ranging from 1.5 and 5 mmol/g carrageenan, a process for preparing this complex and relative controlled release pharmaceutical compositions containing it.

Abstract: A method of treating patients having viral infections including herpes simplex virus 1 and 2 infections and human papillomavirus infections by topically administering Product R, a peptide-nucleic acid preparation, by itself or in a composition comprising Product R and other pharmaceutically acceptable carriers for topical administration, is disclosed.

Abstract: A pharmaceutical dosage form particularly suitable for the administration of active principles in multiple therapies is disclosed. The pharmaceutical dosage form is a double capsule where in an internal capsule is placed inside an external one. Each internal and external capsule includes one or more active principles. A double capsule according to the invention is preferably used in triple or quadruple therapies against the microorganisms Helicobacter Pylori. Advantages of this pharmaceutical dosage form consist in providing a simple posology for administration of two and more active principles, allowing the active principles to activate at the right intervals of time and in the preestablished quantities, and preventing interactions between active principles.

Abstract: The invention relates to the use of carbonic acid or CO2 for producing a pharmaceutical or cosmetic preparation for topical application for stabilizing or increasing the epidermal ceramide synthesis rate. This improves the epidermal permeability barrier and reduces the transepidermal water loss. The preparation is additionally suitable for preventing or treating atopic dermatitis (neurodermatitis).